Integrum AB (publ) (INTEG-B.ST)
SEK 18.65
(3.04%)
SEK 18.65
(3.04%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 22.36 Million SEK | 6.08% |
| 2022 | 21.08 Million SEK | 4.78% |
| 2021 | 20.11 Million SEK | 100.25% |
| 2020 | 10.04 Million SEK | 103.73% |
| 2019 | 4.93 Million SEK | 2.81% |
| 2018 | 4.79 Million SEK | 2.93% |
| 2017 | 4.66 Million SEK | 17.88% |
| 2016 | 3.95 Million SEK | 73.63% |
| 2015 | 2.27 Million SEK | 29.45% |
| 2014 | 1.75 Million SEK | 66.8% |
| 2013 | 1.05 Million SEK | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q1 | 24.63 Million SEK | 10.16% |
| 2023 FY | 22.36 Million SEK | 6.08% |
| 2023 Q1 | 21.35 Million SEK | 1.31% |
| 2023 Q4 | 22.36 Million SEK | 3.9% |
| 2023 Q3 | 21.52 Million SEK | 4.04% |
| 2023 Q2 | 20.68 Million SEK | -3.13% |
| 2022 Q2 | 20.31 Million SEK | 1.79% |
| 2022 Q4 | 21.08 Million SEK | -3.39% |
| 2022 FY | 21.08 Million SEK | 4.78% |
| 2022 Q1 | 19.95 Million SEK | -0.8% |
| 2022 Q3 | 21.82 Million SEK | 7.4% |
| 2021 Q3 | 15.44 Million SEK | 2.48% |
| 2021 Q2 | 15.06 Million SEK | 31.48% |
| 2021 Q1 | 11.45 Million SEK | 14.05% |
| 2021 FY | 20.11 Million SEK | 100.25% |
| 2021 Q4 | 20.11 Million SEK | 30.31% |
| 2020 Q3 | 7.51 Million SEK | 26.61% |
| 2020 FY | 10.04 Million SEK | 103.73% |
| 2020 Q4 | 10.04 Million SEK | 33.71% |
| 2020 Q2 | 5.93 Million SEK | 39.58% |
| 2020 Q1 | 4.25 Million SEK | -13.78% |
| 2019 Q4 | 4.93 Million SEK | 12.99% |
| 2019 FY | 4.93 Million SEK | 2.81% |
| 2019 Q1 | 4.51 Million SEK | -5.86% |
| 2019 Q2 | 4.47 Million SEK | -0.95% |
| 2019 Q3 | 4.36 Million SEK | -2.43% |
| 2018 Q4 | 4.79 Million SEK | 9.64% |
| 2018 FY | 4.79 Million SEK | 2.93% |
| 2018 Q1 | 4.66 Million SEK | 0.14% |
| 2018 Q2 | 4.08 Million SEK | -12.41% |
| 2018 Q3 | 4.37 Million SEK | 7.04% |
| 2017 FY | 4.66 Million SEK | 17.88% |
| 2017 Q2 | 5.52 Million SEK | 3.69% |
| 2017 Q1 | 5.33 Million SEK | 34.87% |
| 2017 Q3 | 5.93 Million SEK | 7.34% |
| 2017 Q4 | 4.66 Million SEK | -21.47% |
| 2016 Q4 | 3.95 Million SEK | 19.52% |
| 2016 Q3 | 3.3 Million SEK | 0.0% |
| 2016 Q1 | - SEK | -100.0% |
| 2016 FY | 3.95 Million SEK | 73.63% |
| 2015 FY | 2.27 Million SEK | 29.45% |
| 2015 Q4 | 2.27 Million SEK | 0.0% |
| 2014 FY | 1.75 Million SEK | 66.8% |
| 2013 FY | 1.05 Million SEK | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Acarix AB (publ) | 6.83 Million SEK | -226.977% |
| ADDvise Group AB (publ) | 121.2 Million SEK | 81.55% |
| ADDvise Group AB (publ) | 121.2 Million SEK | 81.55% |
| Arcoma AB | 28.02 Million SEK | 20.213% |
| Bactiguard Holding AB (publ) | 29.64 Million SEK | 24.57% |
| BICO Group AB (publ) | 493.1 Million SEK | 95.465% |
| Boule Diagnostics AB (publ) | 62.4 Million SEK | 64.164% |
| CellaVision AB (publ) | 126.03 Million SEK | 82.258% |
| Clinical Laserthermia Systems AB (publ) | 6.11 Million SEK | -265.69% |
| Chordate Medical Holding AB (publ) | 1.77 Million SEK | -1162.73% |
| C-Rad AB (publ) | 64.09 Million SEK | 65.114% |
| Duearity AB (publ) | 4.15 Million SEK | -437.676% |
| Dignitana AB (publ) | 7.41 Million SEK | -201.659% |
| Episurf Medical AB (publ) | 3.7 Million SEK | -504.377% |
| Getinge AB (publ) | 6.41 Billion SEK | 99.651% |
| Scandinavian Real Heart AB (Publ) | -1.68 Million SEK | 1428.403% |
| Iconovo AB (publ) | -4.86 Million SEK | 559.933% |
| Luxbright AB (publ) | 8000.00 SEK | -279424.313% |
| Mentice AB (publ) | 14.1 Million SEK | -58.55% |
| OssDsign AB (publ) | 4.3 Million SEK | -419.562% |
| Paxman AB (publ) | 19.99 Million SEK | -11.815% |
| Promimic AB (publ) | 330 Thousand SEK | -6676.347% |
| Qlife Holding AB (publ) | 7.29 Million SEK | -206.664% |
| SciBase Holding AB (publ) | 11.91 Million SEK | -87.616% |
| ScandiDos AB (publ) | 22.69 Million SEK | 1.446% |
| Sectra AB (publ) | 36.59 Million SEK | 38.885% |
| Sedana Medical AB (publ) | 42.97 Million SEK | 47.965% |
| Senzime AB (publ) | 20.34 Million SEK | -9.941% |
| SpectraCure AB (publ) | 1.00 SEK | -2236194400.0% |
| Stille AB | 66.55 Million SEK | 66.4% |
| Vitrolife AB (publ) | 413 Million SEK | 94.585% |
| Xvivo Perfusion AB (publ) | 141.6 Million SEK | 84.208% |